GU Cancers 2024 | MAGNITUDE: HRQoL in patients with mCRPC receiving niraparib and abiraterone

Kim Chi, MD, BC Cancer Vancouver Centre, Vancouver, Canada, discusses patient-reported outcomes in the Phase III MAGNITUDE study (NCT03748641). Patients with BRCA1/2-mutant metastatic castration-resistant prostate cancer (mCRPC) were randomized to either receive niraparib with abiraterone or placebo with abiraterone. Health-related quality of life (HRQoL) was maintained in patients receiving niraparib with abiraterone, and were not greatly affected by the associated side effects. This interview took place at the ASCO GU Cancers Symposium 2024 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.